Biogen Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Biogen Inc 公司

Biogen Inc. 是一家全球性生物製藥公司。該公司致力於爲全球患有嚴重和複雜疾病的人們發現、開發和提供先進的治療方法。該公司經營一系列藥物，用於治療多發性硬化症 (MS)、脊髓性肌萎縮症 (SMA)、阿爾茨海默病和肌萎縮側索硬化症 (ALS)。該公司專注於推進其在神經病學、專業免疫學和罕見疾病領域的產品線。其上市產品包括用於治療 MS 的 TECFIDERA、VUMERITY、AVONEX、PLEGRIDY、TYSABRI 和 FAMPYRA；用於治療 SMA 的 SPINRAZA；用於治療弗裏德賴希共濟失調的 SKYCLARYS；用於治療 ALS 的 QALSODY 和用於治療嚴重斑塊狀銀屑病的 FUMADERM。它還與 Eisai 合作，將 LEQEMBI 商業化，用於治療阿爾茨海默病，並與 Sage 合作，將 ZURZUVAE 商業化，用於治療產後抑鬱症 (PPD)。

Biogen Inc簡介



公司代碼BIIB

公司名稱Biogen Inc

上市日期Sep 17, 1991

CEOMr. Christopher A. (Chris) Viehbacher

員工數量7605

證券類型Ordinary Share

年結日Sep 17

公司地址225 Binney Street

城市CAMBRIDGE

上市交易所NASDAQ Global Select Consolidated

國家United States of America

郵編02142

電話17814642000

網址https://www.biogen.com/

公司代碼BIIB

上市日期Sep 17, 1991

CEOMr. Christopher A. (Chris) Viehbacher

Biogen Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Ms. Susan H. Alexander, Esq., J.D.

Executive Vice President, Chief Legal Officer

56.35K

+55.38%

Ms. Caroline D. Dorsa

Independent Chairman of the Board

29.22K

+12.13%

Dr. Ginger Gregory, Ph.D.

Chief Human Resources Officer, Executive Vice President

17.50K

+28.86%

Ms. Nicole Murphy

Executive Vice President - Pharmaceutical Operations and Technology

14.22K

+1.19%

Dr. Stephen A. Sherwin, M.D.

Independent Director

12.35K

+23.75%

Mr. Rachid Izzar

Executive Vice President, Head of Global Product Strategy and Commercialization

11.23K

-16.53%

Mr. Jesus B. Mantas

Independent Director

8.42K

+39.19%

Ms. Priya Singhal, M.D.

Executive Vice President, Head of Development

5.77K

-8.22%

Dr. Maria C. Freire, Ph.D.

Independent Director

5.47K

+76.33%

Ms. Susan Langer

Independent Director

3.79K

+166.90%

名稱

名稱/職務

職務

持股

持股變動

Ms. Susan H. Alexander, Esq., J.D.

Executive Vice President, Chief Legal Officer

56.35K

+55.38%

Ms. Caroline D. Dorsa

Independent Chairman of the Board

29.22K

+12.13%

Dr. Ginger Gregory, Ph.D.

Chief Human Resources Officer, Executive Vice President

17.50K

+28.86%

Ms. Nicole Murphy

Executive Vice President - Pharmaceutical Operations and Technology

14.22K

+1.19%

Dr. Stephen A. Sherwin, M.D.

Independent Director

12.35K

+23.75%

Mr. Rachid Izzar

Executive Vice President, Head of Global Product Strategy and Commercialization

11.23K

-16.53%

收入明細

單位: USD更新時間: 10月6日週一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

業務USD

名稱

營收

佔比

MS product revenues-TYSABRI

839.80M

31.74%

Spinal Muscular Atrophy-SPINRAZA

543.00M

20.53%

MS product revenues-Fumarate

405.90M

15.34%

MS product revenues-Interferon

246.70M

9.33%

Biosimilar product revenues-BENEPALI

112.10M

4.24%

其他

498.00M

18.82%

地區USD

名稱

營收

佔比

United States

1.38B

52.21%

Rest of World

937.60M

35.44%

United states-Revenues from anti-CD20 therapeutic

467.30M

17.66%

Rest of World-Other revenues

244.60M

9.25%

業務

地區

業務USD

名稱

營收

佔比

MS product revenues-TYSABRI

839.80M

31.74%

Spinal Muscular Atrophy-SPINRAZA

543.00M

20.53%

MS product revenues-Fumarate

405.90M

15.34%

MS product revenues-Interferon

246.70M

9.33%

Biosimilar product revenues-BENEPALI

112.10M

4.24%

其他

498.00M

18.82%

股東統計

更新時間: 8月19日週二

持股股東

股東類型

持股股東

佔比

The Vanguard Group, Inc.

11.74%

PRIMECAP Management Company

10.78%

BlackRock Institutional Trust Company, N.A.

5.59%

State Street Global Advisors (US)

5.09%

Wellington Management Company, LLP

3.27%

其他

63.53%

持股股東

佔比

The Vanguard Group, Inc.

11.74%

PRIMECAP Management Company

10.78%

BlackRock Institutional Trust Company, N.A.

5.59%

State Street Global Advisors (US)

5.09%

Wellington Management Company, LLP

3.27%

其他

63.53%

股東類型

持股股東

佔比

Investment Advisor

51.55%

Investment Advisor/Hedge Fund

24.28%

Hedge Fund

8.68%

Pension Fund

2.62%

Research Firm

2.27%

Sovereign Wealth Fund

1.59%

Bank and Trust

1.38%

Individual Investor

0.17%

Venture Capital

0.14%

其他

7.32%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

1987

135.68M

92.54%

-8.70M

2025Q2

2075

135.74M

92.58%

-12.69M

2025Q1

2149

136.82M

93.38%

-11.44M

2024Q4

2130

138.58M

94.69%

-5.19M

2024Q3

2109

135.95M

93.33%

-6.54M

2024Q2

2116

135.72M

93.21%

-7.14M

2024Q1

2121

136.44M

93.87%

-5.95M

2023Q4

2151

135.61M

93.59%

-2.07M

2023Q3

2177

132.42M

91.43%

-7.53M

2023Q2

2240

133.77M

92.42%

-4.86M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

The Vanguard Group, Inc.

17.21M

11.74%

+255.44K

+1.51%

Jun 30, 2025

PRIMECAP Management Company

15.80M

10.78%

-141.14K

-0.89%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

8.19M

5.59%

-504.36K

-5.80%

Jun 30, 2025

State Street Global Advisors (US)

7.47M

5.09%

+71.90K

+0.97%

Jun 30, 2025

Wellington Management Company, LLP

4.80M

3.27%

+125.98K

+2.70%

Jun 30, 2025

Geode Capital Management, L.L.C.

3.92M

2.67%

+71.29K

+1.85%

Jun 30, 2025

Point72 Asset Management, L.P.

3.83M

2.61%

+3.42M

+840.86%

Jun 30, 2025

Invesco Capital Management (QQQ Trust)

3.00M

2.05%

-10.62K

-0.35%

Aug 31, 2025

Norges Bank Investment Management (NBIM)

2.26M

1.54%

-61.02K

-2.62%

Jun 30, 2025

Invesco Capital Management LLC

2.04M

1.39%

+32.06K

+1.59%

Jun 30, 2025

持股ETF



更新時間: 10月6日週一

機構名稱

佔比

iShares Neuroscience and Healthcare ETF

3.81%

First Trust NASDAQ Pharmaceuticals ETF

3.54%

VanEck Biotech ETF

3.36%

First Trust NYSE Arca Biotechnology Index Fund

3.19%

Invesco Pharmaceuticals ETF

2.45%

SPDR S&P Biotech ETF

2.31%

First Trust Health Care Alphadex Fund

2.26%

Invesco Nasdaq Biotechnology ETF

1.98%

ProShares Ultra Nasdaq Biotechnology

1.97%

iShares Health Innovation Active ETF

1.96%

iShares Neuroscience and Healthcare ETF

佔比3.81%

First Trust NASDAQ Pharmaceuticals ETF

佔比3.54%

VanEck Biotech ETF

佔比3.36%

First Trust NYSE Arca Biotechnology Index Fund

佔比3.19%

Invesco Pharmaceuticals ETF

佔比2.45%

SPDR S&P Biotech ETF

佔比2.31%

First Trust Health Care Alphadex Fund

佔比2.26%

Invesco Nasdaq Biotechnology ETF

佔比1.98%

ProShares Ultra Nasdaq Biotechnology

佔比1.97%

iShares Health Innovation Active ETF

佔比1.96%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據